NCT04396626View on ClinicalTrials.gov

HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes

TerminatedOBSERVATIONAL
Enrollment

975

Participants

Timeline

Start Date

November 18, 2019

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2020

Conditions
Breast Cancer
Trial Locations (1)

10017

Pfizer United States, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04396626 - HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes | Biotech Hunter | Biotech Hunter